JDRF and Novo Nordisk have announced that they are partnering in an attempt to discover and develop novel immunotherapies to prevent, treat, and…
BioLineRx, a biopharmaceutical development company based in Israel, announced that research underlying its EDP 10 project for the treatment of type 1 diabetes won the Hebrew University's prestigious Kaye Innovation Award for...
JDRF-funded researchers at Harvard School of Public Health have found that an experimental drug, called TUDCA, can dramatically reduce the occurrence of type 1 diabetes...
People get diabetes because they’re fat. They get diabetes because they don’t exercise. They get it because they’re lazy and they lack discipline in controlling their appetites. They get diabetes because they’re out of shape slobs. People get diabetes because they deserve it....
Positive results from the first feasibility study of an advanced first-generation artificial pancreas system were presented at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System...
Halozyme Therapeutics announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority. Further...
Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim's investigational novel basal insulin analog, LY2605541, show that that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than Lantus (insulin glargine) in patients...
Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California...
Eli Lilly and Boehringer Ingelheim presented new data from a phase 2b open-label extension study, showing empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1c) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks...
Eli Lilly and Boehringer Ingelheim presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin, marketed under the name Tradjenta in the U.S, at the American Diabetes Association's (ADA) 72nd Scientific Sessions. The new studies...